These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2353985)

  • 41. Chemical and biological characterization of 4'-iodo-4'-deoxydoxorubicin.
    Barbieri B; Giuliani FC; Bordoni T; Casazza AM; Geroni C; Bellini O; Suarato A; Gioia B; Penco S; Arcamone F
    Cancer Res; 1987 Aug; 47(15):4001-6. PubMed ID: 3607745
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat.
    Hirano S; Wakazono K; Agata N; Iguchi H; Tone H
    Drugs Exp Clin Res; 1994; 20(4):153-60. PubMed ID: 7813387
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159).
    Herman EH; Ferrans VJ; Bhat HB; Witiak DT
    Cancer Chemother Pharmacol; 1987; 19(4):277-81. PubMed ID: 3594714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protective effect of a direct renin inhibitor in acute murine model of cardiotoxicity and nephrotoxicity.
    Rashikh A; Pillai KK; Najmi AK
    Fundam Clin Pharmacol; 2014 Oct; 28(5):489-500. PubMed ID: 24117488
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypoxia as a risk factor for doxorubicin-induced cardiotoxicity: a NMR evaluation.
    Bradamante S; Monti E; Paracchini L; Perletti G
    Biochem Biophys Res Commun; 1989 Sep; 163(2):682-8. PubMed ID: 2783116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angiotensin II and aldosterone receptor binding in rat heart and kidney: response to chronic angiotensin II or aldosterone administration.
    Sun Y; Weber KT
    J Lab Clin Med; 1993 Oct; 122(4):404-11. PubMed ID: 8228554
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models.
    Burade V; Bhowmick S; Maiti K; Zalawadia R; Ruan H; Thennati R
    BMC Cancer; 2017 Jun; 17(1):405. PubMed ID: 28587612
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of glutathione and N-acetylcysteine on in vitro and in vivo cardiac toxicity of doxorubicin.
    Villani F; Galimberti M; Monti E; Piccinini F; Lanza E; Rozza A; Favalli L; Poggi P; Zunino F
    Free Radic Res Commun; 1990; 11(1-3):145-51. PubMed ID: 2074045
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats.
    Fadillioğlu E; Erdoğan H; Söğüt S; Kuku I
    J Appl Toxicol; 2003; 23(1):71-4. PubMed ID: 12518339
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx
    Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T
    Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myocardial contractility and heart pharmacokinetics of adriamycin following a single administration in rat.
    Monti E; Piccinini F; Villani F; Favalli L
    Cancer Chemother Pharmacol; 1986; 18(3):289-91. PubMed ID: 3802385
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigations on the antitumor efficacy of liposome-associated doxorubicin in murine tumor models.
    Gabizon A; Goren D; Barenholz Y
    Isr J Med Sci; 1988; 24(9-10):512-7. PubMed ID: 3204005
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipids and lipoprotein profile in doxorubicin treated rats: influence of alpha-tocopherol administration.
    Geetha A; Catherine J; Sankar R; Devi CS
    Indian J Exp Biol; 1990 Nov; 28(11):1071-4. PubMed ID: 2283173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Beneficial effects of carbon monoxide-releasing molecule-2 (CORM-2) on acute doxorubicin cardiotoxicity in mice: role of oxidative stress and apoptosis.
    Soni H; Pandya G; Patel P; Acharya A; Jain M; Mehta AA
    Toxicol Appl Pharmacol; 2011 May; 253(1):70-80. PubMed ID: 21443895
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of the toxicity of distamycin derivatives on cancer cell lines and rat heart.
    Agen C; Sironi AM; Danesi R; Costa M; Bernardini N; Paparelli A; Della Torre P; Del Tacca M
    Toxicology; 1992 Nov; 75(3):209-19. PubMed ID: 1455430
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.
    Herman EH; Zhang J; Ferrans VJ
    Cancer Chemother Pharmacol; 1994; 35(2):93-100. PubMed ID: 7987999
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.
    de Beer EL; Bottone AE; van Rijk MC; van der Velden J; Voest EE
    Br J Pharmacol; 2002 Apr; 135(7):1707-14. PubMed ID: 11934811
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mediation of subacute anthracycline cardiotoxicity in rabbits by cardiac histamine release.
    Bristow MR; Kantrowitz NE; Harrison WD; Minobe WA; Sageman WS; Billingham ME
    J Cardiovasc Pharmacol; 1983; 5(6):913-9. PubMed ID: 6196562
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Angiotensin II-induced hypertension enhanced therapeutic efficacy of liposomal doxorubicin in tumor-bearing mice.
    Hattori Y; Ubukata H; Kawano K; Maitani Y
    Int J Pharm; 2011 Jan; 403(1-2):178-84. PubMed ID: 20934498
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alleviation of doxorubicin-induced nephrotoxicity and hepatotoxicity by chrysin in Wistar rats.
    Rashid S; Ali N; Nafees S; Ahmad ST; Arjumand W; Hasan SK; Sultana S
    Toxicol Mech Methods; 2013 Jun; 23(5):337-45. PubMed ID: 23256457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.